BACKGROUND AND AIMS: Mild neurocognitive dysfunction and altered cerebral proton magnetic resonance spectroscopy ((1) H-MRS) have been demonstrated in patients with chronic hepatitis C (CHC). This longitudinal study aimed to quantify these abnormalities in a cohort of patients free from correlated risk factors and determine whether treatment-induced viral clearance abolished these abnormalities. METHODS: Treatment-naïve, non-cirrhotic patients with CHC, rigorously screened and excluded for other causes of impaired neurocognition, underwent neurocognitive testing, (1) H-MRS and evaluation for quality of life (QOL), mood and fatigue, before and 6 months after the completion of antiviral therapy. A comparison group of healthy controls was similarly assessed at baseline and 1 year later. RESULTS: Post-treatment results in 40 patients with CHC [31 sustained virological responders, hepatitis C virus (HCV)-R and 9 non-responders, HCV-NR] were compared with their pretreatment results, and with the baseline and follow-up assessments of 39 healthy controls. Before receiving treatment, patients had impaired learning efficiency, poorer QOL and higher fatigue scores compared with the controls. Viral clearance was associated with a significant albeit small improvement in the QOL score that did not reach control levels. Cerebral (1) H-MRS demonstrated a lower N-acetyl aspartate/creatine (CRE) ratio in the globus pallidus (GP) of patients with hepatitis C, which was unchanged with viral clearance. The GP choline/CRE ratio increased in HCV-R following treatment, without a correlation with cognitive measures. CONCLUSIONS: The hepatitis C virus has a measurable effect on CNS integrity in patients screened for other medical and/or psychiatric comorbidities. Viral clearance has not been demonstrated to abolish these abnormalities.
BACKGROUND AND AIMS: Mild neurocognitive dysfunction and altered cerebral proton magnetic resonance spectroscopy ((1) H-MRS) have been demonstrated in patients with chronic hepatitis C (CHC). This longitudinal study aimed to quantify these abnormalities in a cohort of patients free from correlated risk factors and determine whether treatment-induced viral clearance abolished these abnormalities. METHODS: Treatment-naïve, non-cirrhotic patients with CHC, rigorously screened and excluded for other causes of impaired neurocognition, underwent neurocognitive testing, (1) H-MRS and evaluation for quality of life (QOL), mood and fatigue, before and 6 months after the completion of antiviral therapy. A comparison group of healthy controls was similarly assessed at baseline and 1 year later. RESULTS: Post-treatment results in 40 patients with CHC [31 sustained virological responders, hepatitis C virus (HCV)-R and 9 non-responders, HCV-NR] were compared with their pretreatment results, and with the baseline and follow-up assessments of 39 healthy controls. Before receiving treatment, patients had impaired learning efficiency, poorer QOL and higher fatigue scores compared with the controls. Viral clearance was associated with a significant albeit small improvement in the QOL score that did not reach control levels. Cerebral (1) H-MRS demonstrated a lower N-acetyl aspartate/creatine (CRE) ratio in the globus pallidus (GP) of patients with hepatitis C, which was unchanged with viral clearance. The GP choline/CRE ratio increased in HCV-R following treatment, without a correlation with cognitive measures. CONCLUSIONS: The hepatitis C virus has a measurable effect on CNS integrity in patients screened for other medical and/or psychiatric comorbidities. Viral clearance has not been demonstrated to abolish these abnormalities.
Authors: Erin E Morgan; Steven Paul Woods; Alexandra Rooney; William Perry; Igor Grant; Scott L Letendre Journal: Clin Neuropsychol Date: 2012-04-26 Impact factor: 3.535
Authors: Felix Kleefeld; Sophie Heller; Patrick Ingiliz; Heiko Jessen; Anders Petersen; Ute Kopp; Antje Kraft; Katrin Hahn Journal: J Neurovirol Date: 2018-05-21 Impact factor: 2.643
Authors: Jordan E Cattie; Scott L Letendre; Steven Paul Woods; Fatma Barakat; William Perry; Mariana Cherner; Anya Umlauf; Donald Franklin; Robert K Heaton; Tarek Hassanein; Igor Grant Journal: J Neurovirol Date: 2014-10-18 Impact factor: 2.643
Authors: Marilyn Huckans; Bret Fuller; Viva Wheaton; Sarah Jaehnert; Carilyn Ellis; Michael Kolessar; Daniel Kriz; Jeanne Renee Anderson; Kristin Berggren; Hannah Olavarria; Anna W Sasaki; Michael Chang; Kenneth D Flora; Jennifer M Loftis Journal: J Psychosom Res Date: 2014-08-07 Impact factor: 3.006
Authors: Nasser Semmo; Beat Müllhaupt; Lisa Ruckstuhl; Lorenzo Magenta; Olivier Clerc; Ralph Torgler; David Semela Journal: PLoS One Date: 2020-11-04 Impact factor: 3.240